Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, September 23, 2012

Reneuron (RENE.L) Files 2 Clinical Trial Applications in UK

Up to you in the UK if you want to get involved.  Ask about the intramuscular injection site, why there?
http://www.proactiveinvestors.com/columns/scimitar-equity/2101/reneuron-renel-files-2-clinical-trial-applications-in-uk-2101.html
ReNeuron submitted 2 applications to UK regulatory authority to commence multi-site ischemic stroke P2 clinical trial to examine efficacy of ReN001 and ReN009 for Critical Limb Ischemia (CLI).

The ReN001 ischemic stroke trial is designed to recruit from a well-defined population of patients between 2 and 4 months after their stroke, which they believe will be the optimum treatment window for the therapy.
The ongoing PISCES study with ReN001 continues on plan following the commencement of treatment of patients in the penultimate dose cohort last month, there remain no cell-related serious adverse events reported in any of the patients treated to date. The independent Data Safety Monitoring Board for the study will shortly make its recommendation regarding treatment of the remaining patients in the penultimate dose cohort. In June of this year, interim data from the PISCES study from the first 5 patients treated was presented by the Glasgow clinical team at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan. Reductions in neurological impairment and spasticity were observed in all 5 patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.
RENE.L also submitted application to UK regulatory authority to commence a P1 clinical trial of ReN009 stem cell therapy for critical limb ischemia (CLI). These patients will be administered via straightforward intramuscular injection of the cells.
The Bottom Line:  But … it is a competitive trial and market arena … Athersys (ATHX) is also pursuing a P2 clinical trial in ischemic stroke. ATHX believes its MultiStem therapy can help limit the associated damage that occurs post ischemic stroke by down-regulating the immune response that follows. ATHX is now conducting a 140-patient trial with data expected in 2H13. MultiStem is a drug-like stem cell product that is produced by obtaining a special class of stem cells from healthy, consenting donors. These cells express proteins and other factors involved in tissue repair and immune system regulation and act through multiple mechanisms, such as protecting damaged or injured cells, reducing inflammation and promoting new blood vessel formation in areas of ischemic injury.  Aastrom (ASTM)is recruiting for its P3 CLI trial which is on-going and headed to completion. This trial will assess the efficacy and safety of ixmyelocel-T in CLI patients. REVIVE will be conducted in the United States across 80 sites and is targeting an enrollment of just under 600 no-option CLI patients. REVIVE represents the largest randomized, double-blind, placebo controlled, multicenter study ever conducted in patients with CLI.  Pluristem (PSTI) reported CLI P1 results in 11/11 of 27 patients in Germany. The PLX-PAD cells therapy failed in 4 of the 27 patients, giving a rate was 85.2% after 12 months for the PLX-PAD cells therapy.  However, little has been heard since … stated it was planning to conduct its P2/3 trials for CLI in the 2H11.

2 comments:

  1. How to I sign my 49 year old boyfriend for the clinical trial? Above web site did not work. He has global aphasia from feb 26 stroke. Physically is fine.

    ReplyDelete
    Replies
    1. You'll have to look at the reneuron site directly.
      General enquiries: info@reneuron.com
      10 Nugent Rd
      Surrey Research Park
      Guildford, Surrey
      GU2 7AF
      UK

      Telephone: +44 (0)1483 302560
      Fax: +44 (0)1483 534864

      Delete